Compositions comprising ketorolac tromethamine at a therapeutically effective concentration of less than 0.5% are disclosed herein. Methods of treating or preventing ocular pain using said compositions are also disclosed herein.

THE PRESENT INVENTION PROVIDES AN AQUEOUS OPHTHALMIC SOLUTION COMPRISING AN EFFECTIVE AMOUNT OF KETOROLAC WHICH COMPRISES CARBOXYMETHYL CELLULOSE IN AN AQUEOUS SOLUTION WHEREIN SAID CONCENTRATION OF CARBOXYMETHYL CELLULOSE IS SELECTED TO PROVIDE AN INCREASED ABSORPTION OF KETOROLAC IN THE EYE OF A PATIENT THAT IS AT LEAST 130% GREATER THAN THE ABSORPTION OF A COMPARATIVE AQUEOUS KETOROLAC OPHTHALMIC SOLUTION HAVING THE SAME CONCENTRATION OF KETOROLAC. (NO SUITABLE

The present invention relates to use of fixed dose combination comprising Ketorolac or its pharmaceutically acceptable salts thereof and Difluprednate for the treatment of post operative ocular inflammation. The present invention further relates to a pharmaceutical composition comprising fixed dose combination comprising Ketorolac or its pharmaceutically acceptable salts thereof and Difluprednate for the treatment of post operative ocular inflammation.

The prevent invention relates to a liquid pharmaceutical composition for treating a patient having moderate to severe pain. The liquid pharmaceutical composition comprises an effective amount of ketorolac or ketorolac tromethamine, and an effective amount of tramadol or its pharmaceutically acceptable salt. The liquid pharmaceutical composition is effective in reducing pain score from 8-9 to 5.3 or less.

The present invention refers to pharmaceutical compositions with an analgesic and/or anti-inflammatory effect, which comprise the combination of quercetin and ketorolac and the use of said composition intended for treating moderate to severe pain. The purpose of the present invention is to combine quercetin, a natural product, with ketorolac a non-steroidal anti-inflammatory analgesic widely used for treating moderate-severe pain.

The present invention is directed to a stable formulation of a combination of ketorolac (non-steroidal anti-inflammatory drug) with olopatadine (anti-histaminic drug) intended for ophthalmic use. This pharmaceutical composition is used for treatment of ophthalmic diseases and conditions particularly seasonal ocular surface allergy.

The present invention is directed to a stable formulation of a combination of ketorolac (non-steroidal anti-inflammatory drug) with olopatadine (anti-histaminic drug) intended for ophthalmic use. This pharmaceutical composition is used for treatment of ophthalmic diseases and conditions particularly seasonal ocular surface allergy.

Admixing carbon dioxide with an aqueous ketorolac solution is useful for increasing the stability of ketorolac in the carbon dioxide-admixed solution.